Pacira BioSciences, Inc. · NASDAQ:PCRX

Pacira BioSciences — North American Neuromodulation Society 2024 Annual Meeting

13 slides from Pacira BioSciences's conference presentation, 2024

  1. Slide 1: Randomized Controlled Trial: Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for Chronic Low Back Pain

    Randomized Controlled Trial: Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for Chronic Low Back Pain Martin G. Ferrillo,1 O’Dane Brady,2 Kasandra Cliff,3 Mihyun Chang,2 Mary DiGiorgi2 Presenter: Kasandra Cliff, MSN, RN Administrator, Northway Surgery and Pain Center 1Albany and

  2. Slide 2: Introduction

    Introduction • Chronic low back pain is a common condition Liquid N2O cartridge often treated with RFA1,2 >850 psi • However, RFA can be destructive to tissue surrounding the boiling point targeted nerves2 (−88° C) • Cryoneurolysis is an alternative treatment to RFA that applies cold temperatures (b

  3. Slide 3: Methods: Study Design

    Methods: Study Design Study design Original follow-up Study extension period • This single-center randomized RFA + RFA + controlled trial (NCT06016127) Screening steroid injection‡ (n=15) steroid injection‡ (n=12) included participants with facet- and mediated chronic low back pain diagnostic nerve

  4. Slide 4: Results: Pain Outcomes

    Results: 9 Adjusted LSM NRS pain scores through 360 days*,† 8 7 Pain Outcomes LSM NRS pain score 6 5 4 3 2 • Adjusted LSM NRS pain scores were 1 numerically higher with RFA versus 0 cryoneurolysis after Day 7 of treatment • Cryoneurolysis was associated with a RFA Cryoneurolysis significant decrease

  5. Slide 5: Results: ODI Outcomes

    Adjusted LSM ODI scores through 360 days*,† 30 25 Results: ODI Outcomes LSM ODI score 20 15 10 • At Day 360, ODI scores were 5 significantly lower with 0 cryoneurolysis versus RFA RFA Cryoneurolysis LSM ODI score P value 180 days RFA (95% CI; n=15) 18.1 (13.6, 22.6) Cryoneurolysis (95% CI; n=15) 13.

  6. Slide 6: Results: Change in Disability Status

    Time and No disability, Mild, Moderate, Severe, Completely disabled, Results: Change in treatment n n (%) n (%) n (%) n (%) n (%) Baseline 0 15 0 3 (20.0) 10 (66.7) 2 (13.3) RFA Cryoneurolysis 15 0 5 (33.3) 6 (40.0) 4 (26.7) 0 Disability Status Day 60 15 3 (20.0) 8 (53.3) 2 (13.3) 1 (6.7) 1 (6.7) RF

  7. Slide 7: Results: PGIC Outcomes

    Results: Adjusted LSM PGIC score through 360 days* 6 PGIC Outcomes 5 LSM PGIC score 4 3 2 • Cryoneurolysis was associated with 1 significant PGIC improvements versus RFA at Day 360 0 RFA Cryoneurolysis LSM PGIC score P value 180 days RFA (95% CI; n=15) 3.6 (2.6, 4.7) Cryoneurolysis (95% CI; n=15) 2.

  8. Slide 8: Results: Participant Satisfaction

    Participant satisfaction over time* Results: 100 Participant 90 Satisfaction 80 Percentage of participants satisfied 70 • More participants were satisfied with pain management after 60 cryoneurolysis than with RFA from 50 Day 240 through Day 360 40 30 20 10 0 RFA Cryoneurolysis 8 | NANS | 2024 Annua

  9. Slide 9: Results: Safety and Additional Spinal Injection

    Results: Safety and Additional Spinal Injection • No serious adverse events were observed over the course of the study • One mild adverse event was reported (compression fracture in the cryoneurolysis group) and was considered unrelated to study treatment by the investigator • After Day 180, 54.5% o

  10. Slide 10: Conclusions

    Participants who received cryoneurolysis without a steroid injection for low back pain had significant improvements in pain, disability, and overall impression of treatment at Day 360 compared with participants who received RFA with a concomitant steroid injection Additionally, participants who rece

  11. Slide 11: Backup

    Backup North American Neuromodulation Society | 2024 Annual Meeting

  12. Slide 12: Results: Baseline Characteristics

    Results: Baseline RFA (n=15) Cryoneurolysis (n=15) Total (N=30) Characteristics Demographic and baseline characteristics Age, mean (SD), y Sex, n (%) 63.1 (12.7) 66.0 (17.1) 64.5 (14.9) • Of 30 total participants, 15 received RFA Male 7 (46.6) 9 (60.0) 16 (53.3) and 15 received cryoneurolysis Female

  13. Slide 13: Results: ODI Outcomes

    Mean percent change in ODI from baseline* Results: ODI Outcomes Mean ODI percent change from baseline 0 -5 • The mean percent decrease in ODI -10 score from baseline was greatest at Day 360 for cryoneurolysis compared -15 with RFA -20 -25 -30 -35 -40 RFA Cryoneurolysis 13 | NANS | 2024 Annual Meetin

Pacira BioSciences — North American Neuromodulation Society 2024 Annual Meeting on 6ix